Cochrane · systematic review · CD011439
Exhaled nitric oxide levels to guide treatment for children with asthma
Petsky, HL, Kew, KM, Chang, AB · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 33.3%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tailoring asthma treatment using fractional exhaled nitric oxide versus clinical symptoms
Population: children with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants who had ≥ 1 exacerbations over study period (48.5 weeks) Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms | OR 0.62 [0.49, 0.8] | 8 studies · 1279 participants | Moderate Downgraded: risk of bias |
Number of asthma exacerbations per 52 weeks (exacerbation rate) Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms | no estimate extracted | 4 studies · 736 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
ICS dose at final visit (budesonide equivalent) Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms | no estimate extracted | 3 studies · 317 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |